Application Detail
Description of Medical Service
Brexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.Description of Medical Condition
Acute lymphoblastic leukaemia is a blood cancer that appears suddenly and grows rapidly. It starts when immature white blood cells called blasts become cancerous.Reason for Application
Highly Specialised Therapy - National Health Reform AgreementMedical Service Type
Therapeutic technologyPrevious Application Number/s
Not ApplicableAssociated Documentation
Application Form
Application Form (PDF 1044 KB)Application Form (Word 787 KB)
Consultation Survey
Consultation Survey (PDF 323 KB)Consultation Survey (Word 72 KB)
PASC Consultation
Expedited – Bypassed PASC
MSAC Consultation
MSAC consultation input closed Friday, 7 October 2022.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
PICO Confirmation
-Assessment Report
-Public Summary Document
Public Summary Document (PDF 1396 KB)Public Summary Document (Word 1119 KB)